AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
16.8 C
New York
Wednesday, October 21, 2026

Tag: diseases

Allergy/Immunology Leaders Unite to Strengthen the Specialty Workforce and Expand Access to High Quality Care

Allergy/Immunology organizations share their commitment to support the specialty workforce, quality care, and continued improvement in clinical outcomesWASHINGTON, June 9, 2026 /PRNewswire/ -- Leaders...

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen launches Healthcare Services initiative to evaluate MSO and CRO acquisitions with potential to support approximately $100M in annual revenue.

Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics

New Program Connects Biotech and Pharmaceutical Partners with Einstein's Aging Research Expertise and Scientific Infrastructure BRONX, N.Y., June 9, 2026 /PRNewswire/ -- Albert Einstein...

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).

Selagine Plasma to Advance Pooled Plasma Eye Drops for Moderate-to-Severe Dry Eye

Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

UNHCR Recognizes Climate-Resilient Drinking Water Planning Tool as Global Compact on Refugees Good Practice

UNHCR recognizes EPHI’s LSLRCC as a Global Compact on Refugees Good Practice supporting climate-resilient drinking water planning.

Duke-NUS awarded €2 million EU grant to help Asia detect outbreaks earlier through wastewater surveillance

EU-funded project will help countries build early-warning systems to spot infectious disease threats before clinical cases surge SINGAPORE, June 9, 2026 /PRNewswire/ -- Duke-NUS...

FloBiotech Announces Agreement with UCLA Health® to Advance Neurodegenerative Disease Therapeutics

BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in neurodegeneration.

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson’s Disease Programme

Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases